- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01288612
Comparative Effectiveness of Endoscopic Assessment of Gastroesophageal Reflux and Barretts Esophagus (challenge)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Barrett's esophagus (BE), a well-known complication of Gastroesophageal Reflux (GER), is the strongest known precursor of esophageal adenocarcinoma. Thus, identifying effective screening approaches for the early detection of BE are highly desired. Current impediments to BE screening include 1) the inability to utilize sedated endoscopy (sEGD) effectively in populations and 2) current GER-based paradigms for detecting BE. Referral center studies demonstrate comparable accuracy between unsedated transnasal endoscopy (uTNE) and sEGD. However, patient acceptability and diagnostic yield with uTNE in general populations remain unknown.
Using the Rochester, Minnesota Epidemiology Project resources, random samples of Olmsted County residents were drawn, and those subjects were mailed validated gastrointestinal symptom questionnaires. These surveys allowed identification of a cohort of community subjects well characterized by the frequency of reflux symptoms. Eligible subjects who were greater than or equal to 50 years old, and who had no previous history of endoscopic evaluation and who were not known to have BE were randomized, stratified by age, sex, and reflux symptoms, and assigned to one of the 3 arms of the study. Subjects in each arm who met the eligibility criteria were initially sent generic invitation letters asking if they agreed to be contacted by phone in two weeks' time to inform them about a research study. If potential subjects explicitly declined to be contacted they were excluded from the study. Eligible subjects were contacted by telephone and only offered the endoscopy technique they had been randomized to. Subjects who accepted and signed an informed consent document were treated according to their randomized assignment and all 3 groups were followed up in the same manner.
Biopsies were taken from any endoscopically suspected BE and from the gastroesophageal junction and squamous mucosa in all subjects. The length of BE segment was defined using Prague criteria. All participants received a telephone call from the research coordinator 1 and 30 days after the procedure to complete validated tolerability scales and adverse events questionnaires.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Mayo Clinic in Rochester
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Olmsted county, Minnesota resident
- Age 50 or older
- Able to give informed consent
Exclusion Criteria:
- History of known Barretts Esophagus (BE) or endoscopy within the last 10 years
- History of progressive dysphagia
- Known Zenkers or epiphrenic diverticulum
- History of recurrent epistaxis
- Illnesses that impair ability to complete questionnaires (e.g. metastatic cancer, stroke, dementia)
- Contraindication to esophageal biopsy (such as anticoagulation using warfarin or clopidogrel).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Screening
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Sedated Endoscopy
Sedated esophagogastroduodenoscopy with biopsy
|
The sedated esophagogastroduodenoscopy procedures were performed using a conventional high-definition endoscope (GIF-180, Olympus America, Center Valley, Pennsylvania) under conscious sedation with intravenous midazolam and fentanyl.
|
Active Comparator: Transnasal Endoscopy at Hospital Unit
Unsedated transnasal endoscopy at hospital unit.
|
Unsedated transnasal endoscopy performed using the EndoSheath transnasal esophagoscope (TNL-5000, Vision Sciences).
Topical anesthetic aerosol spray was applied to the posterior pharynx and nasal spray mixture was applied to the patients nares 10-15 minutes before the endoscopy procedure.
|
Active Comparator: Transnasal Endoscopy at Mobile Unit
Unsedated transnasal endoscopy in mobile research van
|
Unsedated transnasal endoscopy performed using the EndoSheath transnasal esophagoscope (TNL-5000, Vision Sciences).
Topical anesthetic aerosol spray was applied to the posterior pharynx and nasal spray mixture was applied to the patients nares 10-15 minutes before the endoscopy procedure.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Subjects Who Agreed to Participated in the Esophageal Assessment
Time Frame: Approximately 2 weeks after invitation letter was sent
|
This outcome measure was defined as the proportion of subjects who agreed to undergo esophageal assessment in the three groups out of those who were eligible to be contacted for participation in screening.
|
Approximately 2 weeks after invitation letter was sent
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate of Successful Intubation
Time Frame: Visit 1
|
The rate of successful intubation was defined as the ability to traverse the upper esophageal sphincter and visualize the esophageal mucosa and classified as successful or unsuccessful.
|
Visit 1
|
Rate of Complete Evaluation
Time Frame: Visit 1
|
The rate of complete evaluation was defined as visualization of the whole esophagus and identification of landmarks: squamocolumnar junction, gastroesophageal junction (upper margin of gastric folds with stomach deflated), and the diaphragmatic hiatus.
The categories of evaluation were classified as complete (all three landmarks identified), incomplete (some landmarks identified), or unsuccessful.
|
Visit 1
|
Rate of Acquisition of Biopsies From the Esophagus
Time Frame: Visit 1
|
Visit 1
|
|
Mean Duration of Procedure
Time Frame: Visit 1
|
Duration of the procedure was defined as time from the beginning of the procedure (initiation of sedation or local anesthesia) to extubation.
|
Visit 1
|
Mean Time From Extubation to Discharge
Time Frame: Visit 1
|
This outcome measures the recovery time after the procedure.
|
Visit 1
|
Mean Tolerability Scores
Time Frame: Day 1 after the procedure
|
Validated pain scales (where 0 is none and 10 is severe) were used to assess the degree of pain, choking, gagging, and anxiety experienced during the procedure.
Overall tolerance was rated on a scale from 0 to 10, where 0 is good, and 10 is poor tolerance.
|
Day 1 after the procedure
|
Acceptability
Time Frame: Day 1 after the procedure
|
Acceptability was defined as the proportion of subjects willing to undergo the procedure again in the future.
|
Day 1 after the procedure
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Prasad G. Iyer, MD, Mayo Clinic
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 10-007787
- UL1TR000135 (U.S. NIH Grant/Contract)
- RC4DK090413 (U.S. NIH Grant/Contract)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Barrett's Esophagus
-
Northwell HealthMayo Clinic; NinePoint MedicalCompletedBarrett's Esophagus Without Dysplasia | Barrett's Esophagus With Dysplasia | Barrett's Esophagus With Low Grade Dysplasia | Barrett's Esophagus With High Grade Dysplasia | Barrett's Esophagus With Dysplasia, UnspecifiedUnited States
-
Case Comprehensive Cancer CenterCompletedShort Segment Barrett's Esophagus | Long Segment Barrett's EsophagusUnited States
-
The Guthrie ClinicActive, not recruiting
-
Interscope, Inc.RecruitingBarrett's Esophagus With DysplasiaUnited States, Sweden, United Kingdom
-
Mayo ClinicCompletedBarrett's Esophagus With DysplasiaUnited States
-
Massachusetts General HospitalEnrolling by invitationBarrett Esophagus | Barrett's Esophagus Without Dysplasia | Barretts Esophagus With DysplasiaUnited States
-
Lucid Diagnostics, Inc.CompletedBarrett Esophagus | Esophageal Adenocarcinoma | Barrett's Esophagus Without Dysplasia | Barretts Esophagus With DysplasiaUnited States, Spain
-
University of CambridgeUniversity of NottinghamRecruitingBarrett's OesophagusUnited Kingdom
-
Johns Hopkins UniversityAmerican Society for Gastrointestinal Endoscopy; Pentax Medical CorporationCompletedBarrett's Esophagus, Esophageal Intraepithelial NeoplasiaUnited States, Germany
-
Mayo ClinicFred Hutchinson Cancer CenterCompletedBarrett's Esophagus With High Grade Dsyplasia | Early Esophageal CancerUnited States
Clinical Trials on Sedated Endoscopy
-
Abant Izzet Baysal UniversityCompletedPostoperative Pain | Anxiety | Spinal Anesthesia | Perioperative Care | Total Knee Arthroplasty | Music Therapy | Vital SignsTurkey
-
Sheba Medical CenterCompleted
-
Southeast University, ChinaCompleted
-
University of LeipzigCompleted
-
University of UtahEpitel, Inc.TerminatedSleep | Sleep DeprivationUnited States
-
Weill Medical College of Cornell UniversityUnknownInterventional Endoscopy Database for Pancreatico-biliary, Gastrointestinal and Esophageal DisordersColorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Cholangiocarcinoma | Bile Duct Cancer | Cholangitis | Barrett's Esophagus | Gallstones | Choledocholithiasis | Bile Leak | Obstructive Jaundice | Duodenal Cancer | Pancreatic Pseudocysts | Ampullary Cancer | Biliary Strictures | Recurrent Pancreatitis | Bile Duct... and other conditionsUnited States
-
Chinese University of Hong KongCompletedGastrointestinal Bleeding | Bleeding Peptic Ulcer | Active BleedingChina
-
Unidade Local De Saúde Do Norte AlentejanoNOVA Medical SchoolRecruiting
-
Jagiellonian UniversityCompleted
-
University of CalgaryNimble Science Ltd.CompletedIrritable Bowel Syndrome | Proof of ConceptCanada